Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation

dc.contributor.authorEser, Barış
dc.contributor.authorYayar, Özlem
dc.contributor.authorBüyükbakkal, Mehmet
dc.contributor.authorErdoğan, Bülent
dc.contributor.authorErcan, Zafer
dc.contributor.authorMerhametsiz, Özgür
dc.contributor.authorHaspulat, Ayhan
dc.contributor.authorGök Oğuz, Ebru
dc.contributor.authorDoğan, İbrahim
dc.contributor.authorCanbakan, Başol
dc.contributor.authorAylı, M. Deniz
dc.date.accessioned2019-05-13T09:07:26Z
dc.date.available2019-05-13T09:07:26Z
dc.date.issued2015
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractBackground: Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. In chronic kidney disease (CKD), circulating FGF-23 levels are markedly elevated and independently associated with mortality. Left ventricular hypertrophy (LVH) is a potent risk factor for mortality in CKD, and FGFs have been implicated in the pathogenesis of myocardial hypertrophy. In addition, the effect of anemia on CV disease and LVH is well known in CKD. A relation between iron and FGF-23 metabolism is mentioned in a few studies. The aim of this study was to test the association of FGF-23 levels with echocardiographic (ECHO) and iron parameters in peritoneal dialysis patients (PD). Methods: In this cross-sectional study, 61 subjects with PD (29 women and 32 men, mean age: 46.9 ± 13.3 years, mean PD vintage: 69.5 ± 39 months) underwent echocardiograms to assess left ventricular mass index (LVMI). Medical treatments and average values of the basic laboratory results of the last 6 months for all patients were recorded. Serum FGF-23 concentrations were measured using intact FGF-23 (iFGF-23) human enzyme-linked immunosorbent assay (ELISA) kit. According to the median levels of serum FGF-23 the patients were grouped into two (FGF-23 high and low groups). Results: Significant positive correlation was recorded between serum FGF-23 levels and LVMI (P= 0.023). There was also significant difference in terms of hemoglobin (12.1 ± 2 versus 11.0 ± 2, P= 0.017), transferrin saturation (TSAT) (24.9 ± 16.8 versus 19.5 ± 10.8, P= 0.042) between low and high FGF-23 group. Also in linear regression analysis the negative relation between FGF-23 and hemoglobin is persisted (r= 0.199, P= 0.045). Conclusions: FGF-23 is associated with LVMI, anemia and low TSAT in patients with PD. Whether increased FGF-23 is a marker or a potential mechanism of myocardial hypertrophy and anemia in patients with end-stage renal disease (ESRD) requires further study. © 2015 Sociedad Española de Nefrología.
dc.identifier.citationEser, B., Yayar, O., Büyükbakkal, M., Erdoğan, B., Ercan, Z., Merhametsiz, O., Haspulat, A., Gök Oğuz, E. [et.al.]. (2015). Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation. Nefrologia, 35(5), 465-472.
dc.identifier.doi10.1016/j.nefroe.2015.10.007
dc.identifier.endpage472en_US
dc.identifier.issn2013-2514
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage465en_US
dc.identifier.urihttps://doi.org/10.1016/j.nefroe.2015.10.007
dc.identifier.urihttps://hdl.handle.net/11491/1802
dc.identifier.volume35en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Espana S.L.
dc.relation.ispartofNefrologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAnemiaen_US
dc.subjectFibroblast Growth Factor 23en_US
dc.subjectLeft Ventricular Mass Indexen_US
dc.subjectPeritoneal Dialysisen_US
dc.titleFibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation
dc.typeArticle

Dosyalar